Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
REVIEW PAPER
Hypertension in selected rheumatic diseases
Online publication date: 2012-11-06
Reumatologia 2012;50(5):425-431
KEYWORDS
ABSTRACT
Hypertension is a serious health problem both in Poland and worldwide. About 10% of high blood pressure cases are secondary hypertension and they include those caused by rheumatic diseases. Renal and blood vessel damage play the main role in its pathogenesis, leading to increase of blood volume, secretion of vasoactive factors and increase of vessel resistance (Fig. 1). Therefore hypertension is very frequent in patients with systemic lupus erythematosus, vasculitis and systemic sclerosis. Hypertension is also present in a significant number of patients with gout. It is important to remember that some drugs that are in wide use in rheumatology may increase blood pressure or interfere with hypotensive treatment. Due to the serious complications of hypertension it is necessary to aim for early diagnosis of hypertension and its effective treatment (Table I).
REFERENCES (52)
1.
Tykarski A, Posadzy-Małaczyńska A, Wyrzykowski B i wsp. Rozpowszechnianie nadciśnienia tętniczego oraz skuteczność jego leczenia u dorosłych mieszkańców naszego kraju: wyniki programu WOBASZ. Kardiol Pol 2005; 63 (supl. 4): S614-S619. .
2.
Lawes CM, Bennett DA, Lewington S, Rodgers A. Blood pressure and coronary heart disease: a review of the evidence. Semin Vasc Med 2002; 2: 355-368.
3.
Russell D, Dahl A, Lund C. Stroke – primary prophylaxis. Tidsskr Nor Laegeforen 2007; 127: 754-758.
4.
Kannel WB. Incidence and epidemiology of heart failure. Heart Fail Rev 2000; 5: 167-173.
5.
Januszewicz A. Kłębuszkowe zapalenia nerek w przebiegu układowych zapaleń naczyń. W: Nadciśnienie tętnicze – zarys patogenezy, diagnostyki i leczenia. Januszewicz A (red.). Medycyna Praktyczna, Kraków 2007; 197-198.
6.
Szczepańska-Sadowska E. Fizjologiczne i patofizjologiczne mechanizmy rozwoju nadciśnienia nerkopochodnego. W: Nadciśnienie nerkopochodne. Januszewicz A, Szmidt J, Więcek A (red.). Medycyna Praktyczna, Kraków 2003; 13-39.
7.
Messerli FH, Ventura HO, Amodeo C. Osler’s maneuver and pseudohypertension. N Engl J Med 1985; 312: 1548-1551.
8.
Roman MJ, Devereux RB, Schwartz JE, et al. Arterial stiffness in chronic inflammatory diseases. Hypertension 2005; 46: 194-199.
9.
Verdecchia P, Schillaci G, Borgioni C, et al. Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension 1998; 32: 983-988.
10.
Rapp CA, Berner B, Müller GA, Reuss-Borst MA. Long-term analysis of clinical disease activity and chronic organ damage in patients with systemic lupus erythematosus. Z Rheumatol 2002; 61: 521-531.
11.
Lilleby V, Flato B, Forre O. Disease duration, hypertension and medication requirements are associated with organ damage in childhood-onset systemic lupus erythematosus. Clin Exp Rheumatol 2005; 23: 261-269.
12.
Mikdashi J, Handwerger B, Langenberg P, et al. Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus. Stroke 2007; 38: 281-285.
13.
Korkmaz C, Cansu DU, Kașifogˇlu T. Myocardial infarction in young patients ( 35 years of age) with systemic lupus erythematosus: a case report and clinical analysis of the literature. Lupus 2007; 16: 289-297. .
14.
Manger K, Manger B, Repp R, et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 2002; 61: 1065-1070. .
15.
Koller H, Waldenberger P, Mayer G, et al. Renovascular hypertension in a patient with systemic lupus erythematosus and secondary antiphospholipid antibody syndrome. Lupus 2005; 14: 566-568. .
16.
Remondino GI, Mysler E, Pissano MN, et al. A reversible bilateral renal artery stenosis in association with antiphospholipid syndrome. Lupus 2000; 9: 65-67.
17.
Hernández D, Dominguez ML, Diaz F, et al. Renal infarction in a severely hypertensive patient with lupus erythematosus and antiphospholipid antibodies. Nephron 1996; 72: 298-301. .
18.
Karim MY, Alba P, Tungekar MF, et al. Hypertension as the presenting feature of the antiphospholipid syndrome. Lupus 2002; 11: 253-256. .
19.
Riccialdelli L, Arnaldi G, Giacchetti G, et al. Hypertension due to renal artery occlusion in a patient with antiphospholipid syndrome. Am J Hypertens 2001; 14: 62-65.
20.
Blaustein DA, Kumbar L, Srivastava M, et al. Polyarteritis nodosa presenting as isolated malignant hypertension. Am J Hypertens 2004; 17: 380-381.
21.
Pagnoux C, Seror R, Henegar C, et al. French Vasculitis Study Group: Clinical features and outcomes In 348 patients with polyarteritis nodosa: a systemic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum 2010; 62: 616-626. .
22.
Thel MC, Mannon RB, Allen NB. Hyperrenin-hyperaldosterone-dependent malignant hypertension in polyarteritis nodosa. South Med J 1993; 86: 1400-1402.
23.
Uyama H, Shiiki H, Watanabe T, Dohi K. A case of polyarteritis nodosa presenting with multiple intrarenal aneurysms and accelerated hypertension. Nippon Jinzo Gakkai Shi 1995; 37: 57-61.
24.
Vora J, Cooper J, Thomas JP. Polyarteritis nodosa presenting with hypertensive encephalopathy. Br J Clin Pract 1992; 46: 144-145.
25.
Guillevin L, Le Thi Huong D, Godeau P, et al. Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: a study in 165 patients. Br J Rheumatol 1988; 27: 258-264.
26.
Bajema IM, Hagen EC, van der Woude FJ, et al. Wegener’s granulomatosis: a meta-analysis of 349 literary case reports. J Lab Clin Med 1997; 129: 17-22. .
27.
Jamoussi SK, Ben Dhaou B, Boussema F, et al. Unusual presentation of Wegener’s granulomatosis. Rev Med Interne 2010; 31: 16-18.
28.
Schillinger F, Denis PS, Dion JJ, et al. Severe Schönlein-Henoch nephritis in adults. A report of twenty cases. Nephrologie 2000; 21: 247-252.
29.
Lasseur C, Rispal P, Combe C, et al. Rheumatoid purpura in adults. Apropos of 40 cases. Rev Med Interne 1996; 17: 381-389.
30.
Cybulska I, Florczak E, Januszewicz M i wsp. Leczenie nadciśnienia naczyniowo-nerkowego w przebiegu choroby Takayasu – opis przypadku. Nadciśnienie Tętnicze 2003; 7: 121-128.
31.
Steen VD, Mayes MD, Merkel PA. Assessment of kidney involvement. Clin Exp Rheumatol 2003; 21 (Suppl 29): S29-S31.
32.
Teixeira L, Servettaz A, Mehrenberger M, et al. Scleroderma renal crisis. Presse Med 2006; 35: 1966-1974.
33.
Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000; 133: 600-603.
34.
Hasegawa S, Iesato K, Tsukahara T, et al. Successful use of angiotensin II receptor antagonist (losartan) in a patient with scleroderma renal crisis. Nippon Jinzo Gakkai Shi 2000; 42: 60-65.
35.
Penn H, Denton CP. Diagnosis, management and prevention of scleroderma renal disease. Curr Opin Rheumatol 2008; 20: 692-696.
36.
Nguyen B, Mayes MD, Arnett FC, et al. HLA–DRB1*0407 and *1304 are risk factors for scleroderma renal crisis. Arthritis Rheum 2011; 63: 530-534.
37.
Zakopoulos NA, Kotsis VT, Gialafos EJ, et al. Systemic sclerosis is not associated with clinical or ambulatory blood pressure. Clin Exp Rheumatol 2003; 21: 199-204.
38.
Shilkina NP, Iunonin IE, Stoliarova SA, et al. Arterial hypertension in patients with systemic connective tissue disease and hemorrhagic vasculitis. Ter Arkh 2010; 82: 40-45. .
39.
Klocke R, Cockcroft JR, Taylor GJ, et al. Arterial stiffness and central blood pressure, as determined by pulse wave analysis, in rheumatoid arthritis. Ann Rheum Dis 2003; 62: 414-418.
40.
Gonzalez-Gay MA, Gonzalez-Juanatey C, Miranda-Filloy JA, et al. Cardiovascular disease in rheumatoid arthritis. Biomed Pharmacother 2006; 60: 673-677.
41.
Niklas A, Tykarski A. Nadciśnienie tętnicze a dna moczanowa – indywidualizacja terapii. Świat Medycyny 2003; 11: 18-22.
42.
Würzner G, Gerster JC, Chiolero A, et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001; 19: 1855-1860. .
43.
Kelly JJ, Mangos G, Williamson PM, et al. Cortisol and hypertension. Clin Exp Pharmacol Physiol Suppl 1998; 25: S51-S56.
44.
Whitworth JA, Kelly JJ, Brown MA, et al. Glucocorticoids and hypertension in man. Clin Exp Hypertens 1997; 19: 871-884.
45.
Międzybrodzki R, Świerkot J, Szechiński J. Leki stosowane w reumatologii a układ krążenia. Terapia 2005; 3: 6-12.
46.
Głuszek J, Tykarski A, Jankowska K. Czy wskazane jest jednoczesne stosowanie aspiryny i inhibitorów konwertazy angiotensyny? Pol Arch Med Wewn 2005; 114: 906-912.
47.
Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure. Ann Intern Med 1994; 121: 289-300.
48.
Morgan T, Anderson A. The effect of nonsteroidal anti-inflammatory drugs on blood pressure in patients treated with different antihypertensive drugs. J Clin Hypertens (Greenwich) 2003; 5: 53-57.
49.
Świerkot J, Gruszecka-Marczyńska K, Szechiński J. Sześciomiesięczne badanie oceniające skuteczność i bezpieczeństwo stosowania cyklosporyny u chorych na reumatoidalne zapalenie stawów. Reumatologia 2005; 43: 257-264.
50.
Kellner H, Bornholdt K, Hein G. Leflunomide in the treatment of patients with early rheumatoid arthritis – results of a prospective non–interventional study. Clin Rheumatol 2010; 29: 913-920.
51.
Labarca C, Massardo L, Garcia PI, et al. Effectiveness of infliximab in patients with inflammatory arthritis refractory to conventional treatment. Rev Med Chil. 2003; 131: 1157-1164.
52.
Wang PS, Avorn J, Brookhart MA, et al. Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives. Hypertension 2005; 46: 273-279.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
